|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 92 No. 5 (September 1), 1998:
pp. 1617-1625
Phosphorothioate Oligonucleotides Inhibit the Intrinsic Tenase
Complex
John P. Sheehan and
Hao-Chang Lan
From the University of Texas Health Science Center at San Antonio,
Department of Medicine/Hematology, San Antonio, TX.
Systemic administration of ISIS 2302, a 20-mer antisense
phosphorothioate oligonucleotide targeting human intercellular adhesion molecule-1 mRNA, causes prolongation of plasma clotting times in both
monkey and human studies. The anticoagulant effects of ISIS 2302 were
investigated with both in vitro coagulation assays in human plasma and
purified enzyme systems. At high oligonucleotide plasma concentrations
(>100 µg/mL), prolongation of the prothrombin and
thrombin times was observed. In a thrombin time assay using purified
components, high concentrations of ISIS 2302 inhibited thrombin
clotting activity both by stimulating inhibition by heparin cofactor II
and directly competing with fibrinogen for binding to anion binding
exosite I. In contrast, low concentrations of ISIS 2302 (<100
µg/mL) showed a selective, linear prolongation of the activated
partial thromboplastin time (PTT). The rate limiting effect of 50 µg/mL ISIS 2302, which prolonged the PTT to 1.5 times control, was
identified by sequential modification of the clotting assay. Delaying
addition of oligonucleotide until after contact activation failed to
correct prolongation of the PTT. The calcium-dependent steps of the
intrinsic pathway were individually assessed by adding sufficient
activated coagulation factor to correct the PTT in plasma deficient in
that specific factor. Addition of factor XIa, IXa, VIIIa, or Va failed
to correct the PTT in the presence of ISIS 2302. In contrast, 0.2 nmol/L factor Xa corrected prolongation of the PTT in factor
X-deficient plasma with or without oligonucleotide present. ISIS 2302 (50 µg/mL) did not prolong a modified Russel viper venom time,
suggesting no significant inhibition of prothrombinase. Thus, 50 µg/mL ISIS 2302 prolonged the PTT by selectively inhibiting intrinsic
tenase activity. ISIS 2302 showed partial inhibition of intrinsic
tenase activity (to approximately 35% of control) at clinically
relevant oligonucleotide concentrations in a chromogenic assay. This
activity was oligonucleotide sequence-independent but required the
phosphorothioate backbone, suggesting that inhibition of intrinsic
tenase is a general property of this class of oligonucleotides. These
results are relevant to both the therapeutic use of phosphorothioate oligonucleotides and the potential design of inhibitors of the intrinsic tenase complex, a novel target for anticoagulation.
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. D. Linnik, A. M. O'Rourke, and M. A. Crowther
Pharmacokinetics of High-Dose Abetimus Sodium in Normal Subjects With Specific Assessment of Effect on Coagulation
J. Clin. Pharmacol.,
August 1, 2008;
48(8):
909 - 918.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Goel, K. Desai, A. Bulgaru, A. Fields, G. Goldberg, S. Agrawal, R. Martin, M. Grindel, and S. Mani
A Safety Study of a Mixed-backbone Oligonucleotide (GEM231) Targeting the Type I Regulatory Subunit {alpha} of Protein Kinase A Using a Continuous Infusion Schedule in Patients with Refractory Solid Tumors
Clin. Cancer Res.,
September 15, 2003;
9(11):
4069 - 4076.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Farman and D. J. Kornbrust
Oligodeoxynucleotide Studies in Primates: Antisense and Immune Stimulatory Indications
Toxicol Pathol,
January 1, 2003;
31(1_suppl):
119 - 122.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. L. Sewell, R. S. Geary, B. F. Baker, J. M. Glover, T. G. K. Mant, R. Z. Yu, J. A. Tami, and F. A. Dorr
Phase I Trial of ISIS 104838, a 2'-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-alpha
J. Pharmacol. Exp. Ther.,
December 1, 2002;
303(3):
1334 - 1343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B R Yacyshyn, W Y Chey, J Goff, B Salzberg, R Baerg, A L Buchman, J Tami, R Yu, E Gibiansky, and W R Shanahan
Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease
Gut,
July 1, 2002;
51(1):
30 - 36.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Geary, T. A. Watanabe, L. Truong, S. Freier, E. A. Lesnik, N. B. Sioufi, H. Sasmor, M. Manoharan, and A. A. Levin
Pharmacokinetic Properties of 2'-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats
J. Pharmacol. Exp. Ther.,
March 1, 2001;
296(3):
890 - 897.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. C. Cunningham, J. T. Holmlund, J. H. Schiller, R. S. Geary, T. J. Kwoh, A. Dorr, and J. Nemunaitis
A Phase I Trial of c-Raf Kinase Antisense Oligonucleotide ISIS 5132 Administered as a Continuous Intravenous Infusion in Patients with Advanced Cancer
Clin. Cancer Res.,
May 1, 2000;
6(5):
1626 - 1631.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. A. M. Anderson, J. C. Fredenburgh, A. R. Stafford, Y. S. Guo, J. Hirsh, V. Ghazarossian, and J. I. Weitz
Hypersulfated Low Molecular Weight Heparin with Reduced Affinity for Antithrombin Acts as an Anticoagulant by Inhibiting Intrinsic Tenase and Prothrombinase
J. Biol. Chem.,
March 23, 2001;
276(13):
9755 - 9761.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
